On December 10, 2025, Citius Oncology, Inc. (CTOR) announced the closing of a $18 million registered direct offering and private placement. The 8-K filing disclosed that the company issued shares at a purchase price of $1.09 each, with gross proceeds intended to support commercialization efforts.

The financing follows the recent FDA approval of LYMPHIR (denileukin diftitox), a treatment for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) who had at least one prior systemic therapy. According to the filing, management estimates the initial market for LYMPHIR exceeds $400 million and is underserved by existing therapies.

"Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies." — Citius Oncology, Inc., SEC 8-K Filing

The company stated in the filing that it will use the proceeds to fund commercialization activities for LYMPHIR, including market education, securing reimbursement, and maintaining product supply. The offering closed on December 10, 2025, the same day as the filing, under a registration statement that became effective on September 4, 2025.

Citius Oncology identified several risk factors in the filing, including the need for substantial additional funds to operate as a going concern for at least the next 12 months. The company also noted challenges related to physician and patient acceptance in a competitive landscape and reliance on third-party logistics providers and specialty pharmacies.